RU2016108652A - Способы лечения спорадического миозита с тельцами включений - Google Patents
Способы лечения спорадического миозита с тельцами включений Download PDFInfo
- Publication number
- RU2016108652A RU2016108652A RU2016108652A RU2016108652A RU2016108652A RU 2016108652 A RU2016108652 A RU 2016108652A RU 2016108652 A RU2016108652 A RU 2016108652A RU 2016108652 A RU2016108652 A RU 2016108652A RU 2016108652 A RU2016108652 A RU 2016108652A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- sequence
- variable region
- heavy chain
- light chain
- Prior art date
Links
- 201000002481 Myositis Diseases 0.000 title claims 47
- 210000003000 inclusion body Anatomy 0.000 title claims 47
- 238000000034 method Methods 0.000 title claims 33
- 150000001413 amino acids Chemical class 0.000 claims 56
- 102000004472 Myostatin Human genes 0.000 claims 41
- 108010056852 Myostatin Proteins 0.000 claims 41
- 239000005557 antagonist Substances 0.000 claims 41
- 229950006326 bimagrumab Drugs 0.000 claims 23
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 230000037396 body weight Effects 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000019505 Deglutition disease Diseases 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000003863 physical function Effects 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000009747 swallowing Effects 0.000 claims 2
- 210000001364 upper extremity Anatomy 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865861P | 2013-08-14 | 2013-08-14 | |
| US61/865,861 | 2013-08-14 | ||
| US201461983567P | 2014-04-24 | 2014-04-24 | |
| US61/983,567 | 2014-04-24 | ||
| PCT/IB2014/063904 WO2015022658A2 (en) | 2013-08-14 | 2014-08-13 | Methods of treating sporadic inclusion body myositis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016108652A true RU2016108652A (ru) | 2017-09-14 |
| RU2016108652A3 RU2016108652A3 (enExample) | 2018-04-28 |
Family
ID=51492992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016108652A RU2016108652A (ru) | 2013-08-14 | 2014-08-13 | Способы лечения спорадического миозита с тельцами включений |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20160200818A1 (enExample) |
| EP (1) | EP3033358A2 (enExample) |
| JP (1) | JP2016528247A (enExample) |
| KR (1) | KR20160042987A (enExample) |
| CN (1) | CN105960414A (enExample) |
| AU (2) | AU2014307589A1 (enExample) |
| BR (1) | BR112016002198A2 (enExample) |
| CA (1) | CA2918300A1 (enExample) |
| CL (1) | CL2016000341A1 (enExample) |
| HK (1) | HK1219280A1 (enExample) |
| IL (1) | IL243883A0 (enExample) |
| MX (1) | MX2016001969A (enExample) |
| PH (1) | PH12016500141A1 (enExample) |
| RU (1) | RU2016108652A (enExample) |
| SG (2) | SG10201801063TA (enExample) |
| TN (1) | TN2016000057A1 (enExample) |
| TW (1) | TW201536318A (enExample) |
| WO (1) | WO2015022658A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA015105B1 (ru) | 2005-11-23 | 2011-06-30 | Акселерон Фарма Инк. | Антагонисты активина - actriia и их применение для стимулирования роста кости |
| IN2014DN10515A (enExample) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN107050424A (zh) | 2007-02-01 | 2017-08-18 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW202104248A (zh) | 2007-02-02 | 2021-02-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| TWI748373B (zh) | 2008-08-14 | 2021-12-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX387164B (es) | 2009-06-12 | 2025-03-19 | Acceleron Pharma Inc | Proteínas de fusión actriib-fc truncadas. |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| MX371442B (es) | 2012-08-24 | 2020-01-30 | Chugai Pharmaceutical Co Ltd | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. |
| EP3308796B1 (en) | 2012-11-02 | 2021-07-14 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| TN2017000217A1 (en) * | 2014-12-08 | 2018-10-19 | Novartis Ag | Myostatin or activin antagonists for the treatment of sarcopenia |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
| CN107771081A (zh) | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
| CN115028721A (zh) * | 2015-12-18 | 2022-09-09 | 中外制药株式会社 | 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR102866147B1 (ko) * | 2016-03-10 | 2025-09-30 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| DK3600415T3 (da) * | 2017-03-24 | 2025-12-01 | Novartis Ag | Antistof mod activin-receptor type ii-receptor til anvendelse ved behandling af hjertesvigt |
| US20200181271A1 (en) * | 2017-06-28 | 2020-06-11 | Novartis Ag | Methods for preventing and treating urinary incontinence |
| CA3092334A1 (en) | 2018-03-01 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
| WO2021014823A1 (ja) * | 2019-07-24 | 2021-01-28 | ソニー株式会社 | 情報処理装置、情報処理方法および情報処理プログラム |
| WO2022153997A1 (ja) * | 2021-01-13 | 2022-07-21 | アステラス製薬株式会社 | ＡｃｔＲＩＩＡ、ＡｃｔＲＩＩＢ及びＦｎ１４に結合する多重特異性抗体 |
| EP4577301A1 (en) * | 2022-08-26 | 2025-07-02 | Versanis Bio, Inc. | Actrii antibody fixed unit dose treatments |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69738670D1 (de) | 1996-10-28 | 2008-06-19 | Inst Suisse De Rech S Experime | Verfahren zur oligomerisation von peptiden |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| ATE309385T1 (de) | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2503697A1 (en) | 2002-10-29 | 2004-05-13 | Borean Pharma A/S | Trimeric binding proteins for trimeric cytokines |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2009539805A (ja) | 2006-06-09 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | 安定化されたインスリン様増殖因子ポリペプチド |
| EP2424895B1 (en) * | 2009-04-27 | 2017-09-06 | Novartis AG | Compositions and methods for increasing muscle growth |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
-
2014
- 2014-08-13 BR BR112016002198A patent/BR112016002198A2/pt not_active IP Right Cessation
- 2014-08-13 SG SG10201801063TA patent/SG10201801063TA/en unknown
- 2014-08-13 KR KR1020167006266A patent/KR20160042987A/ko not_active Withdrawn
- 2014-08-13 US US14/911,333 patent/US20160200818A1/en not_active Abandoned
- 2014-08-13 SG SG11201600212VA patent/SG11201600212VA/en unknown
- 2014-08-13 TN TN2016000057A patent/TN2016000057A1/en unknown
- 2014-08-13 TW TW103127832A patent/TW201536318A/zh unknown
- 2014-08-13 CN CN201480056363.5A patent/CN105960414A/zh not_active Withdrawn
- 2014-08-13 WO PCT/IB2014/063904 patent/WO2015022658A2/en not_active Ceased
- 2014-08-13 MX MX2016001969A patent/MX2016001969A/es unknown
- 2014-08-13 CA CA2918300A patent/CA2918300A1/en not_active Abandoned
- 2014-08-13 JP JP2016533986A patent/JP2016528247A/ja active Pending
- 2014-08-13 EP EP14761413.5A patent/EP3033358A2/en not_active Ceased
- 2014-08-13 HK HK16107243.2A patent/HK1219280A1/zh unknown
- 2014-08-13 RU RU2016108652A patent/RU2016108652A/ru not_active Application Discontinuation
- 2014-08-13 AU AU2014307589A patent/AU2014307589A1/en not_active Abandoned
-
2016
- 2016-01-21 PH PH12016500141A patent/PH12016500141A1/en unknown
- 2016-02-01 IL IL243883A patent/IL243883A0/en unknown
- 2016-02-12 CL CL2016000341A patent/CL2016000341A1/es unknown
-
2017
- 2017-09-13 AU AU2017228600A patent/AU2017228600A1/en not_active Abandoned
- 2017-09-28 US US15/718,091 patent/US20180066061A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016001969A (es) | 2016-06-02 |
| HK1219280A1 (zh) | 2017-03-31 |
| CL2016000341A1 (es) | 2016-10-28 |
| SG10201801063TA (en) | 2018-04-27 |
| CN105960414A (zh) | 2016-09-21 |
| PH12016500141A1 (en) | 2016-04-18 |
| CA2918300A1 (en) | 2015-02-19 |
| AU2017228600A1 (en) | 2017-10-05 |
| WO2015022658A3 (en) | 2015-05-28 |
| RU2016108652A3 (enExample) | 2018-04-28 |
| EP3033358A2 (en) | 2016-06-22 |
| BR112016002198A2 (pt) | 2017-09-12 |
| WO2015022658A2 (en) | 2015-02-19 |
| KR20160042987A (ko) | 2016-04-20 |
| SG11201600212VA (en) | 2016-02-26 |
| JP2016528247A (ja) | 2016-09-15 |
| US20160200818A1 (en) | 2016-07-14 |
| TW201536318A (zh) | 2015-10-01 |
| US20180066061A1 (en) | 2018-03-08 |
| IL243883A0 (en) | 2016-04-21 |
| TN2016000057A1 (en) | 2017-07-05 |
| AU2014307589A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016108652A (ru) | Способы лечения спорадического миозита с тельцами включений | |
| JP2016528247A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| AU2013337775B2 (en) | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof | |
| JP2014519317A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2013538057A5 (enExample) | ||
| JP2015007098A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2014519318A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| JP2007097598A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2016188209A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2012121878A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| SI2530091T1 (en) | PROTITELO ANTI-DLL3 | |
| JP2016515515A5 (enExample) | ||
| JP2014169326A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190405 |